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VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately
predict warfarin dose requirements in some Malaysian patients
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Background/aim: VKORC1 and CYP2C9 genetic polymorphisms may not accurately predict warfarin dose requirements. We evaluated
an existing warfarin dosing algorithm developed for Malaysian patients that was based only on VKORC1 and CYP2C9 genes.
Materials and methods: Five Malay patients receiving warfarin maintenance therapy were investigated for their CYP2C9*2, CYP2C9*3,
and VKORC1-1639G>A genotypes and their vitamin K-dependent (VKD) clotting factor activities. The records of their daily warfarin
doses and international normalized ratio (INR) 2 years prior to and after the measurement of VKD clotting factors activities were
acquired. The mean warfarin doses were compared with predicted warfarin doses calculated from a genotypic-based dosing model
developed for Asians.
Results: A patient with the VKORC1-1639 GA genotype, who was supposed to have higher dose requirements, had a lower mean warfarin
dose similar to those having the VKORC1-1639 AA genotype. This discrepancy may be due to the coadministration of celecoxib, which
has the potential to decrease warfarin’s metabolism. Not all patients’ predicted mean warfarin doses based on a previously developed
dosing algorithm for Asians were similar to the actual mean warfarin dose, with the worst predicted dose being 54.34% higher than the
required warfarin dose.
Conclusion: Multiple clinical factors can significantly change the actual required dose from the predicted dose from time to time.
The additions of other dynamic variables, especially INR, VKD clotting factors, and concomitant drug use, into the dosing model are
important in order to improve its accuracy.
Key words: Warfarin, dosing algorithm, CYP2C9, VKORC1, PCR-RFLP, clotting factor activities

1. Introduction
Warfarin is one of the most important drugs in
personalized medicine. Many clinical conditions may
affect the potency of warfarin over time, thus requiring
patients to regularly visit a healthcare center for dose
adjustment. Traditionally, warfarin dosage is determined
by the international normalized ratio (INR) values, which
are derived from prothrombin time (PT) (1). The difficulty
of achieving the ideal warfarin dose is compounded by
genetic variations that may affect the pharmacokinetics and
pharmacodynamics of warfarin in different individuals.
Research has shown that cytochrome P450 2C9
(CYP2C9) and vitamin K epoxide reductase complex
1 (VKORC1) gene polymorphisms are significantly
associated with warfarin sensitivity (2–5), including
among Asian patients. Several dosing guidelines and
* Correspondence: yungan.chua@gmail.com

algorithms based on genetic data have been proposed in
response to reports that the addition of genetic data into a
nongenetic dosing model may increase the predictability
of the model by up to 16% (6–9). The strong association
of these genes with warfarin sensitivity compelled the US
Food and Drug Administration to recommend conducting
genetic tests before determining the most suitable warfarin
dose range (http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2007/ucm108967.htm.) Although a
few studies have established strong associations between
genotypic data and warfarin dose requirements, the
comprehensive use of these genotypic data in clinical
practice is generally hindered by the lack of evidence of
the overall efficacy of this approach (10), which suggests
that there are other factors that play a role in warfarin
dose variation. This situation is compounded by high
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genetic variability across the world. Although Asians and
Caucasians have different genetic backgrounds, many
drug doses for Asians are still based on data from studies
of Caucasian populations. Furthermore, the inclusion of
additional laboratory tests, such as genetic screening, in
addition to conventional INR is generally not preferred
due to the extra cost involved (11).
In this study, we evaluated an existing warfarin dosing
algorithm developed for Malaysian patients that was based
only on the VKORC1 and CYP2C9 genes.

was then compared to the predicted daily warfarin dose
calculated using an Asian population-based warfarin dosing
model (7). In the previously developed dosing model for
Asian patients (n = 108), age, weight, and CYP2C9*3 and
VKORC1 381 genotypes were processed by the algorithm
and yielded a correlation coefficient of 0.73. In our study,
we replaced the VKORC1 381 genotype with the VKORC11639G>A genotype because these genotypes have been
confirmed to be closely linked with each other and therefore
interchangeable (5). The percentage difference between the
actual and predicted daily warfarin doses was then recorded.

2. Materials and methods
Ethical approval was obtained from the Universiti Sains
Malaysia Research Ethics Committee (USMKK/PPP/
JEPeM [197.3{6}]). Written informed consent was acquired
from all patients before the study. Blood samples (3 mL)
were obtained from 5 Malay patients, between 44 and 81
years old, who had received warfarin treatment. DNA was
extracted from the blood according to the DNA extraction
kit manufacturer’s standard guidelines (QIAGEN, Hilden,
Germany). Each patient was tested for INR and the activity
of the vitamin K-dependent (VKD) clotting factors II, VII,
IX, and X using an STA Compact Benchtop Hemostasis
Analyzer (Diagnostica Stago, Parsippany, NJ, USA). The
CYP2C9*2, CYP2C9*3, and VKORC1-1639G>A genotypes
were determined by using previously reported polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) methods (12,13).
The demographic data, medical records, mean daily
warfarin doses, and INR values 2 years before and after
the measurement of VKD clotting factor activities were
acquired from both the patient’s folder and the hospital
database. The mean warfarin doses were considered to be the
doses required by the patients to maintain their respective
stable INR ranges (2.5–3.5 for atrial valve replacement
or between 2 and 3 for other indications). The mean dose

3. Results
The induction of warfarin therapy and the concomitant
drugs prescribed during a single hospital visit before the
measurement of the current INR and the VKD clotting
factor activities are shown in Table 1. Genotyping results
for the CYP2C9 and VKORC1 polymorphisms are
presented in gel electrophoresis images (Figures 1–3). In
agreement with several findings that support VKORC1
as having a stronger association with warfarin sensitivity
than any other genetic or clinical data (4,14–17), all
patients who had the VKORC1-1639 AA genotype had
a lower warfarin dose requirement compared to patients
with the GA genotype, with the exception of Patient C
(Table 2). However, further investigation of the medication
history of Patient C confirmed that he was also taking
celecoxib, a nonsteroidal antiinflammatory drug that is
also metabolized by CYP2C9 and thus may interact with
warfarin to cause an increase in warfarin sensitivity (18).
The purported “warfarin-sensitive” CYP2C9*2
genotype was not proven to be the cause of warfarin
sensitivity because Patient E, who had a “warfarinsensitive” CYP2C9*2 T allele, actually had the highest
mean warfarin dose compared to other patients. Patient
E also had the VKORC1-1639 G allele, which represents
a “warfarin-resistant” allele. These differences further

Table 1. Related diseases and concomitant drugs prescribed to the patients during 1 hospital visit before the assessment of the INR and
activities of the VKD clotting factors.
Indication of warfarin prescription

Concomitant drugs

Patient A

AVR

Captopril, propranolol

Patient B

CCF, IHD

Aspirin, bisoprolol, digoxin, enalapril, pravastatin, ranitidine, trimetazidine

Patient C

AF, CCF, IHD

Aspirin, atorvastatin, celecoxib, digoxin, enalapril, furosemide

Patient D

AF, CCF, IHD

Aspirin, digoxin, furosemide, potassium chloride

Patient E

AF, CRHD, history of TIA

Digoxin, furosemide, potassium chloride, propranolol

AVR, Atrial valve replacement; CCF, congestive cardiac failure; IHD, ischemic heart disease; AF, atrial fibrillation; CRHD, chronic
rheumatic heart disease; TIA, transient ischemic attack.
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Figure 1. Representative gel electrophoresis image of PCR-RFLP
analysis for CYP2C9*2 for Patient E. The first lane contains a
50-bp DNA ladder, while lanes -ve and +ve are the negative and
positive controls, respectively. The rest of the numbered lanes are
the genotype results for patients not discussed in this study. The
mutant allele (T) was resistant to restriction enzyme digestion;
therefore, it is represented by the 375-bp fragment. The wild-type
allele (C) was digested into 2 fragments of 76 and 299 bp. The
presence of all 3 bands in a single lane indicates that the patient
is heterozygous.

confirm the fact that the VKORC1 genotype is a stronger
determinant of warfarin sensitivity among Asians than
the CYP2C9*2 genotype because the presence of the
“warfarin-resistant” VKORC1 allele can mitigate the effect
of the CYP2C9*2 alleles. These results also explain why the
incorporation of the CYP2C9*2 genotype into a dosing
prediction model was not favored in a univariate analysis
of warfarin dosing models developed for Asian patients as
proposed by Tham et al. (7).
The opposite result was observed for the CYP2C9*3
genotype. Patient A, who had the warfarin-sensitive
CYP2C9*3 C allele, received the lowest warfarin dose of
all 5 patients. The low warfarin dose may be a result of the
combined effects of the warfarin-sensitive genotypes of
the CYP2C9*3 AC and VKORC1-1639 AA alleles. All of
the clotting factor activities in Patient A were also lower
than in other patients. With the exception of Patient C, all
patients with the VKORC1-1639 GA genotype had higher
activities of clotting factors II, IX, and X when compared
to patients who had the VKORC1-1639 AA genotype.
There were significant variations in the dose differences
between actual and predicted mean daily doses among
the 5 investigated patients. Patient D had the largest dose

Figure 2 Representative gel electrophoresis image of PCR-RFLP
analysis for CYP2C9*3 for Patient A. The first lane contains a 50bp DNA marker ladder, while -ve and +ve are the negative and
positive controls, respectively. The rest of the numbered lanes are
the genotype results for patients who are not discussed in this
study. The wild-type allele (A) was resistant to restriction enzyme
digestion; therefore, it is represented as a 105-bp fragment. The
mutant allele (C) was digested into 2 fragments of 85 and 20 bp
(the 20-bp band is not clearly visible in the gel electrophoresis
image). The presence of 105- and 85-bp bands in 1 lane was
sufficient to indicate that the patient is heterozygous.

difference, with a predicted dose deviation of 54.24%
from the actual mean dose. Apparently, Patient D would
be overdosed if the warfarin dose was based on the
recommended genetic-based dosing algorithm. Therefore,
a dosing algorithm that is based solely on genetic data
is inaccurate due to other confounding factors, such as
environmental and clinical conditions. For example,
drug–drug interactions, intake of supplements, intake of
vitamin K, health status, smoking status, and compliance
to warfarin may confound dosing predictions (19–22).
Unlike genetic data, these factors are in a state of constant
change and therefore should be incorporated in the dosing
model. Therefore, genetic data alone can only serve as a
guide, especially during the initiation of warfarin therapy,
because patient response to this anticoagulant is dynamic
and dependent on multiple factors.
4. Discussion
The dosing algorithm could not be applied to all patients.
For example, administration of drugs that may interact
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Figure 3. Representative gel electrophoresis image of PCRRFLP analysis for VKORC1-1639G>A for Patient D. The first
lane contains a 100-bp DNA marker ladder, while -ve and +ve
are the negative and positive controls, respectively. The rest of
the numbered lanes are the genotype results for patients who are
not discussed in this study. The mutant allele (A) was resistant
to restriction enzyme digestion; therefore, it is represented as a
290-bp fragment. The wild-type allele (G) was digested into 2
fragments of 168- and 122-bp. The presence of all 3 bands in a
single lane indicates that the patient is heterozygous.

with warfarin’s pharmacokinetics may render purported
strong predictors of warfarin such as VKORC1-1639 GA
less useful. Therefore, a clinical trial on a larger population
is needed in order to validate the findings and to compare
the algorithm with a conventional dosing method (23).

Because genetic tests are not routinely practiced by
the local medical clinics in Malaysia, the measurement
of VKD clotting factor activities can serve as a useful and
relatively easy method to predict warfarin sensitivity in
patients. Additionally, hemostatic tests can be performed
simultaneously with other routine applications, such
as INR tests. Each individual VKD clotting factor has
a distinct diagnostic value. Factor VII is particularly
sensitive to warfarin administration and may serve as an
indicator for bleeding risk in addition to, or instead of,
INR (24). Because the activity of factor IX is not detected
by a PT test, it is determined independently of the INR
result and can thus be used as a secondary measure for the
determination of warfarin dosing, especially for clinical
situations in which recommendations based solely on INR
data are not effective (25).
A dynamic parameter such as INR must also be
integrated into warfarin dosing models so that the dose can
be adjusted for any changes in a patient’s medical condition.
Some studies also considered the use of drugs that may
interact with warfarin, such as amiodarone, in the warfarin
dosing model (6,9,26). Incorporation of concomitant
drugs into the dosing algorithm is also advantageous for
improved prediction accuracy, as evidenced by the effects
of celecoxib on Patients C’s warfarin dose requirement.
Although there are no studies that correlate VKORC1
polymorphisms with VKD clotting factor activities, several
studies have indicated that VKORC1 polymorphisms may
cause combined VKD clotting factors deficiency when
plasma levels of VKD clotting factors are congenitally

Table 2. Comparison of the CYP2C9*2, CYP2C9*3, and VKORC1-1639 GA genotypes and the activity of VKD clotting factors.
Patient A

Patient B

Patient C

Patient D

Patient E

CYP2C9*2

CC

CC

CC

CC

CT

CYP2C9*3

AC

AA

AA

AA

AA

VKORC1-1639

AA

AA

GA

GA

GA

Factor II (%)

9

16

16

30

32

Factor VII (%)

22

32

37

26

36

Factor IX (%)

20

48

50

59

51

Factor X (%)

9

13

11

18

23

Actual mean dose (mg daily)

2.00

2.30

2.02

3.30

3.48

Predicted dose based on algorithm (mg daily)

2.15

2.20

2.72

5.09

4.74

Dose difference (%)

7.50

−4.35

34.65

54.24

36.21

The CYP2C9*2 C, CYP2C9*3 A, and VKORC1-1639 G alleles are alleles with higher warfarin dose requirements, and their respective
variants have lower dose requirement. A negative dose difference percentage indicates that the predicted warfarin dose is lower than the
actual mean warfarin dose in the patient.
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low (27–29). Future investigation of the role of VKORC1
polymorphisms on the activity of VKD clotting factors
may provide a better understanding of the association of
individual VKD clotting factor activities with VKORC1
polymorphisms.
Stratification of patients based on their genotypes at
specific polymorphic loci may not be the only important
factor when adjusting warfarin doses, despite the fact that
genotypic data can help predict how a patient may respond.
Clinical conditions such as INR and aberrant prothrombin
time, decreased VKD clotting factor activities, and
concomitant drug use can affect a patient’s sensitivity to
warfarin and have the potential to be integrated into the
genetic-based dosing algorithm to better improve dosing
predictions for Malaysian patients.
It is concluded that the current available warfarin
dosing algorithms (6,7,9,30) are useful only if they are

validated in the population for which they are intended
to be used. Nevertheless, due to the limited sample size
in this study, the risk for overdose found does not reduce
the potential of the algorithm as a suitable predictor for
warfarin dose; rather, its effectiveness can be diminished
when some important clinical parameters are overlooked.
In the future, a population-based study with a larger
sample size should be conducted to successfully evaluate
the effectiveness of the algorithm.
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